Abbott's Lingo Continuous Glucose Monitor Now Available In U.S.
Portfolio Pulse from Benzinga Newsdesk
Abbott has launched its Lingo Continuous Glucose Monitor in the U.S., targeting individuals interested in health and wellness. The device offers real-time glucose data and personal coaching insights, and is available without a prescription.
September 05, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott's launch of the Lingo Continuous Glucose Monitor in the U.S. could boost its stock as it taps into the health and wellness market. The device's availability without a prescription may increase its adoption.
The introduction of a new product in the U.S. market, especially one that caters to the growing health and wellness sector, is likely to positively impact Abbott's stock. The device's unique selling points, such as real-time data and no prescription requirement, could drive consumer interest and sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90